Eton Pharmaceuticals Q2 EPS $0.18 Beats $(0.09) Estimate, Sales $12.00M Beat $6.51M Estimate
Portfolio Pulse from mahesh@benzinga.com
Eton Pharmaceuticals (NASDAQ:ETON) reported Q2 earnings of $0.18 per share, beating the analyst consensus estimate of $(0.09) by 300 percent. This is a 400 percent increase over losses of $(0.06) per share from the same period last year. The company also reported quarterly sales of $12.00 million, beating the analyst consensus estimate of $6.51 million by 84.29 percent, a 63.05 percent increase over sales of $7.36 million the same period last year.
August 10, 2023 | 8:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eton Pharmaceuticals reported strong Q2 earnings and sales, significantly beating analyst estimates. This positive financial performance could boost investor confidence and potentially drive the stock price up in the short term.
Eton Pharmaceuticals reported a significant beat on both earnings and sales for Q2, which indicates strong financial performance. This could increase investor confidence in the company and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100